By Stockpickr Staff
Updated at 2:02 p.m. EST on March 2, 2009

Now that was an ugly end to an ugly month. The S&P 500 ended February down more than 10% at a 12-year low.

Of course, it started off with the announcement that the government will take a substantial stake in Citigroup (C), crushing the common shareholders.

That was side by side with news that the economy contracted at a 6.2% annual rate.

Will more banks be “nationalized”? Will things get worse before they get better for the economy? Is it priced in to the market?

With this in mind, we thought we'd take a look at some of the stocks people have been searching for on TheStreet.com and see what Jim Cramer's had to say about them lately.

These stocks could be in the news for a number of reasons. Some require immediate attention while others may not. Regardless, it never hurts to hear what Cramer (or any of the other professional investors on the site) has to say about them. The key is to gather as much information as you can in order to make the most informed investment decisions you can.

In a recent post to his RealMoney blog, Cramer had this to say about Genzyme (GENZ):

“Is health care finished as a concept? I think that you could argue that it is finished as a hiding place. The health care business has been rocked by problems before, and it has managed to bounce back time and again, but this one's really painful because there's nothing but bogeymen out there telling us what is going to happen. We are in a "shoot first, ask questions later" mode. One thing I would point out is that the drug industry has been a remarkable stalwart in Congress, and the president's going to have a tougher time rolling them that he would other industries.

"The real issue for me is valuation. Let's say the president doesn't want Genzyme to get reimbursed the way it has been for orphan drugs. It's been the Democrats, not the Republicans, who have fought for these companies. The Democrats have always held up the group as inventors, not salespeople, so my take is that after the smoke clears, you will come back to that group.

"But is now the time to buy them? I think their outperformance has been too great in the last six months to call a bottom, and the big pharma companies are reeling, too.

"Would I short them here? You should have shorted them two days ago.

"Going long, though? I'd wait, which is why we trimmed the group yesterday for Action Alerts PLUS. My instincts, given congressional love for biotech, though, is that when they settle, you will be surprised the resistance that Obama gets on the issue, particularly the orphan drug issue.”

In afternoon trading on Monday, Genzyme was down 6.9%, or $4.23, to $56.70.

For more of what Cramer's had to say about Friday's top-searched stocks, including Del Monte (DLM), AK Steel (AKS), Wendy's (WEN) and Alcoa (AA), check out the Cramer's Take portfolio on Stockpickr.


P.S. Where is Cramer putting his own money? Take a free peek at his personal portfolio to see all his buys and sells by clicking here. When you do, Jim will also send you exclusive email alerts telling you everything he’s about to add to or shed from his Action Alerts PLUS portfolio -- before he makes his trade.